NCT05942118

Brief Summary

Several localization techniques are now in use for localization of non-palpable breast lesions. Several studies have compared wire guided localization (WGL), which has been for years the gold standard for non-palpable breast lesions' localization, with more modern techniques. Scientific evidence supports the efficacy of the new "wire-free" techniques, which appear to be comparable to the WGL in terms of safe surgical resection, while overcoming limitations associated with logistic difficulties and patient discomfort. There is still limited data in literature on the comparative effectiveness of these modern techniques, and there is no strong evidence that one is superior to the others. In particular, no randomized trials of comparison between ROLL and magnetic seed localization are currently available. The aim of this randomized study is to compare ROLL with magnetic seed to assess their efficacy for non-palpable breast lesions' localization.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
262

participants targeted

Target at P75+ for all trials

Timeline
22mo left

Started May 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress64%
May 2023May 2028

Study Start

First participant enrolled

May 31, 2023

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

June 23, 2023

Completed
19 days until next milestone

First Posted

Study publicly available on registry

July 12, 2023

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2026

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 31, 2028

Expected
Last Updated

June 23, 2026

Status Verified

May 1, 2026

Enrollment Period

3 years

First QC Date

June 23, 2023

Last Update Submit

June 19, 2026

Conditions

Keywords

Non-palpable breast lesion

Outcome Measures

Primary Outcomes (1)

  • Free-surgical margins

    Number of surgical procedures in which surgical margins are disease-free ("no ink on tumor" for invasive cancer and margin of 2 mm for in situ-carcinoma).

    3 years

Secondary Outcomes (7)

  • Excess breast resection

    3 years

  • Surgery Time

    3 years

  • Hospitalization days

    3 years

  • Complications

    3 years

  • Reintervention

    3 years

  • +2 more secondary outcomes

Study Arms (2)

ROLL

Prior to surgery, an ultrasound-guided localization will be performed and albumin marked with Technetium 99m will be injected close to the tumor and in the subareolar area. During surgery, a specific probe will be used to locate the lesion and sentinel lymph node.

Procedure: Breast conservative surgery

SEED

During diagnostic biopsy or prior to surgery, a magnetic clip will be placed in the breast lesion; during surgery, localization will be performed using a specific probe, while sentinel lymph node localisation, when needed, will be performed even with indocyanine green dye (ICG) or methylene blue dye

Procedure: Breast conservative surgery

Interventions

Every patients with non-palpable breast lesion will undergo to conservative breast surgery after lesion's localization

ROLLSEED

Eligibility Criteria

Age18 Years - 85 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Breast cancer patients with non-palpable lesions candidated for surgery

You may qualify if:

  • Female;
  • Non-palpable breast lesions;
  • Indication to lesion's surgical excision (lumpectomy, quadrantectomy)
  • Preoperative diagnosis on histology or cytology of borderline lesion (B3 or C3) or malignant lesion (B4-B5 or C4-C5);
  • Written informed consent.

You may not qualify if:

  • Benign lesion at diagnosis on preoperative core biopsy (B2) or fine needle aspiration (C2);
  • Clinically palpable breast lesion;
  • Breast lesion localization for planned neoadjuvant chemotherapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Istituti Clinici Scientifici Maugeri SpA

Pavia, Lombardy, 27100, Italy

Location

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 23, 2023

First Posted

July 12, 2023

Study Start

May 31, 2023

Primary Completion

May 31, 2026

Study Completion (Estimated)

May 31, 2028

Last Updated

June 23, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share

Locations